Table 2.

Kinase inhibitors in clinical trials for the treatment of neurological disorders.

Kinase	Disease	Agent	Mechanism of action	Therapeutic goal	Clinical trial ID
GSK3β	AD	Tideglusib	Non-ATP competitive inhibitor of GSK3β	Reduction of tau phosphorylation	NCT00948259 NCT01350362 NCT02586935 (USA)
DYRK1A	AD DS	SM07883 Epigallocatechin-3-gallate (EGCG)	ATP competitive inhibitor of DYRK1A Non-ATP competitive inhibitor of DYRK1A	Inhibition of tau hyperphosphorylation, aggregation, and NFT formation Amelioration of DS cognitive symptoms through DYRK1A inhibition	ACTRN12619000327189 (Australia) NCT01394796 (USA)
FYN	AD	Saracatinib	ATP-competitive inhibitor of Src family of tyrosine kinases	Reduced Fyn activation by Aβ	NCT02167256 (USA)
ABL	AD	Nilotinib	ATP competitive inhibitor of ABL	Stabilization of levels of phosphorylated tau, total tau and Aβ	NCT02947893 (USA)
p38 MAPK	AD DLB	Neflamapiod	ATP-competitive inhibitor of p38 MAPK	Decrease neuroinflammatory markers, reduced decline in cognitive function	NCT03402659 NCT03435861 NCT04001517 (USA)
LRRK2	PD	DNL151	Inhibition of LRRK2 kinase	Decrease neuroinflammatory markers	NCT04056689 (USA)